PUBLISHER: IMARC | PRODUCT CODE: 1701963
PUBLISHER: IMARC | PRODUCT CODE: 1701963
The global fertility test market size reached USD 584.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 971.7 Million by 2033, exhibiting a growth rate (CAGR) of 5.52% during 2025-2033.
Fertility tests are performed to diagnose problems that prevent couples from conceiving. They comprise blood tests, pelvic examination, semen analysis, basal body temperature (BBT) charting, post coital test, transvaginal (pelvic) ultrasound exam, hysterosalpingogram or HSG, hysteroscopy, and laparoscopy. They are reliable, valid, and assist in determining a suitable treatment. In addition, they prevent the spread of sexually transmitted infections (STIs) in the body. Fertility tests also help detect cervical cancer and abnormal cells around the cervix. As a result, they are carried out in hospitals, home care, and fertility clinics.
The growing prevalence of diseases, such as polycystic ovary syndrome (PCOS), due to the overproduction of estrogen by the ovaries represents one of the key factors driving the market. Moreover, there is a rise in infertility rates across the globe due to lifestyle changes and increasing stress and obesity, which is caused by a lack of physical exercise and alterations in dietary pattern. This, along with the increasing awareness among the masses about the benefits of fertility tests, is propelling the growth of the market. In addition, the launch of technologically advanced products to treat infertility among the masses is positively influencing the market. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce pregnancy and ovulation test kits for centralizing all fertility-related data. This, coupled with the burgeoning healthcare industry, is offering lucrative growth opportunities to industry investors. Apart from this, there is an increase in the demand for easy-to-use fertility monitors with high accuracy. The rising utilization of artificial intelligence (AI) in sperm analysis is expected to bolster the growth of the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AdvaCare Pharma, Ava AG, Babystart Ltd. (Snowden Healthcare), Church & Dwight Co. Inc., Fairhaven Health LLC, Geratherm Medical AG, Prestige Consumer Healthcare Inc., Quidel Corporation, UEBE Medical GmbH, Valley Electronics AG and viO HealthTech Limited.